Peter L Choyke

List of Publications by Year in Descending Order

151 papers	14,137 citations	52 h-index	118 g-index
164 ext. papers	16,513 ext. citations	9.8 avg, IF	6.37 L-index

#	Paper	IF	Citations
151	CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model.. *OncoImmunology*, **2022**, 11, 2019922	7.2	1
150	Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy.. *Cancer Immunology, Immunotherapy*, **2022**, 1	7.4	2
149	Advancing Research on Medical Image Perception by Strengthening Multidisciplinary Collaboration. *JNCI Cancer Spectrum*, **2022**, 6,	4.6	1
148	Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNDependent Tumor Vessel Regression. *Cancer Research*, **2021**, 81, 3092-3104	10.1	7
147	Translating a Radiolabeled Imaging Agent to the Clinic.. *Advanced Drug Delivery Reviews*, **2021**, 181, 114086	15.5	1
146	Near infrared photoimmunotherapy of cancer; possible clinical applications. *Nanophotonics*, **2021**, 10, 3135-3151	6.3	8
145	Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy. *Cancers*, **2021**, 13,	6.6	12
144	Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. *EBioMedicine*, **2021**, 67, 103345	8.8	9
143	Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. *Radiology*, **2021**, 299, 613-623	20.5	3
142	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 143-151	8.8	8
141	Novel PET imaging methods for prostate cancer. *World Journal of Urology*, **2021**, 39, 687-699	4	2
140	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. *IEEE Access*, **2021**, 9, 87531-87542	3.5	3
139	Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity. *Advanced Therapeutics*, **2021**, 4, 2000269	4.9	13
138	Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation. *Radiotherapy and Oncology*, **2021**, 160, 192-201	5.3	10
137	Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. *Molecular Cancer Therapeutics*, **2021**, 20, 2262-2273	6.1	4
136	Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy. *Cancers*, **2020**, 12,	6.6	12
135	A Grading System for Extraprostatic Extension of Prostate Cancer That We Can All Agree Upon?. *Radiology Imaging Cancer*, **2020**, 2, e190088	1.4	2

134	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. *New England Journal of Medicine*, **2020**, 382, 917-928	59.2	235
133	Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of F-DCFPyL PET/CT with Comparison to Multiparametric MRI. *Radiology*, **2020**, 296, 564-572	20.5	9
132	Combined CD44- and CD25-Targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T Cells in Syngeneic Mouse Cancer Models. *Cancer Immunology Research*, **2020**, 8, 345-355	12.5	25
131	Impact of bowel preparation with FleetSenema on prostate MRI quality. *Abdominal Radiology*, **2020**, 45, 4252-4259	3	15
130	Can Molecular Imaging Measure T-cell Activation?. *Cancer Research*, **2020**, 80, 2975-2976	10.1	4
129	Prospective Evaluation of F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. *American Journal of Roentgenology*, **2020**, 215, 652-659	5.4	7
128	Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models. *Vaccines*, **2020**, 8,	5.3	13
127	Apical periurethral transition zone lesions: MRI and histology findings. *Abdominal Radiology*, **2020**, 45, 3258-3264	3	
126	Near-Infrared Photoimmunotherapy: Photoactivatable Antibody-Drug Conjugates (ADCs). *Bioconjugate Chemistry*, **2020**, 31, 28-36	6.3	34
125	The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy. *Bioconjugate Chemistry*, **2019**, 30, 2624-2633	6.3	22
124	A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. *Radiology*, **2019**, 290, 709-719	20.5	72
123	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. *Cancer Immunology Research*, **2019**, 7, 401-413	12.5	57
122	New Targets for PET Molecular Imaging of Prostate Cancer. *Seminars in Nuclear Medicine*, **2019**, 49, 326-336	5.4	10
121	Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency. *Cancer Biotherapy and Radiopharmaceuticals*, **2019**, 34, 498-503	3.9	4
120	Near-Infrared Photoimmunotherapy of Cancer. *Accounts of Chemical Research*, **2019**, 52, 2332-2339	24.3	160
119	A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy. *Turkish Journal of Urology*, **2019**, 45, 357-365	1.3	9
118	Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer. *Journal of Magnetic Resonance Imaging*, **2018**, 48, 1326-1335	5.6	17
117	Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. *European Radiology*, **2018**, 28, 4407-4417	8	47

116	MRI-Guided Robotically Assisted Focal Laser Ablation of the Prostate Using Canine Cadavers. *IEEE Transactions on Biomedical Engineering*, **2018**, 65, 1434-1442	5	17
115	Future Perspectives and Challenges of Prostate MR Imaging. *Radiologic Clinics of North America*, **2018**, 56, 327-337	2.3	9
114	What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. *Radiology*, **2018**, 286, 186-195	20.5	117
113	Ruling out clinically significant prostate cancer with negative multi-parametric MRI. *International Urology and Nephrology*, **2018**, 50, 7-12	2.3	13
112	Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. *ACS Central Science*, **2018**, 4, 1559-1569	16.8	102
111	MRI Robot for Prostate Focal Laser Ablation: An Ex Vivo Study in Human Prostate. *Journal of Imaging*, **2018**, 4, 140	3.1	5
110	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. *Diagnostic and Interventional Radiology*, **2018**, 24, 46-53	3.2	11
109	Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer. *Cancer Science*, **2018**, 109, 1902-1908	6.9	25
108	Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer. *Radiology*, **2018**, 288, 485-491	20.5	38
107	Detection of prostate cancer in multiparametric MRI using random forest with instance weighting. *Journal of Medical Imaging*, **2017**, 4, 024506	2.6	23
106	Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. *Molecular Cancer Research*, **2017**, 15, 1153-1162	6.6	53
105	The Current State of MR Imaging-targeted Biopsy Techniques for Detection of Prostate Cancer. *Radiology*, **2017**, 285, 343-356	20.5	65
104	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT. *Molecular Cancer Research*, **2017**, 15, 1667-1677	6.6	44
103	Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. *Radiology*, **2017**, 285, 859-869	20.5	94
102	Comparison of planar, PET and well-counter measurements of total tumor radioactivity in a mouse xenograft model. *Nuclear Medicine and Biology*, **2017**, 53, 29-36	2.1	0
101	18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology. *Clinical Nuclear Medicine*, **2017**, 42, 735-740	1.7	19
100	Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges. *Radiology*, **2017**, 285, 728-743	20.5	27
99	Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management. *Seminars in Ultrasound, CT and MRI*, **2017**, 38, 59-71	1.7	8

98	Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. *Journal of Urology*, **2017**, 197, 640-646	2.5	78
97	Robotic System for MRI-guided Focal Laser Ablation in the Prostate. *IEEE/ASME Transactions on Mechatronics*, **2017**, 22, 107-114	5.5	29
96	Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. *Radiology*, **2017**, 285, 147-156	20.5	25
95	Quantitative Image Quality Comparison of Reduced- and Standard-Dose Dual-Energy Multiphase Chest, Abdomen, and Pelvis CT. *Tomography*, **2017**, 3, 114-122	3.1	10
94	Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. *Oncotarget*, **2017**, 8, 10425-10436	3.3	123
93	Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy (3D LC-QPM) after treatment with the near infrared photoimmunotherapy. *Oncotarget*, **2017**, 8, 104295-104302	3.3	13
92	Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer. *Balkan Medical Journal*, **2017**, 34, 388-396	1.5	4
91	PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *European Urology*, **2016**, 69, 16-40	10.2	1682
90	Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. *Science Translational Medicine*, **2016**, 8, 352ra110	17.5	120
89	Advancement of MR and PET/MR in Prostate Cancer. *Seminars in Nuclear Medicine*, **2016**, 46, 536-543	5.4	14
88	Do Radiologists Have Stage Fright? Tumor Staging and How We Can Add Value to the Care of Patients with Cancer. *Radiology*, **2016**, 278, 11-2	20.5	14
87	Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer. *Oncotarget*, **2016**, 7, 79408-79416	3.3	15
86	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e235-45	7.1	22
85	Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. *Oncotarget*, **2016**, 7, 14324-35	3.3	30
84	Robot for Magnetic Resonance Imaging Guided Focal Prostate Laser Ablation1. *Journal of Medical Devices, Transactions of the ASME*, **2016**, 10,	1.3	3
83	Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	59
82	Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. *Journal of Urology*, **2016**, 196, 690-6	2.5	104
81	Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. *Ca-A Cancer Journal for Clinicians*, **2016**, 66, 326-36	220.7	99

80	Near infrared photoimmunotherapy for lung metastases. *Cancer Letters*, **2015**, 365, 112-21	9.9	49
79	Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. *Radiology*, **2015**, 277, 741-50	20.5	256
78	Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 390-7	27.4	999
77	(89)Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies. *Radiology*, **2015**, 275, 490-500	20.5	93
76	Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET. *Current Oncology Reports*, **2015**, 17, 56	6.3	9
75	Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 425.e1-425.e6	2.8	29
74	MRI-based prostate volume-adjusted prostate-specific antigen in the diagnosis of prostate cancer. *Journal of Magnetic Resonance Imaging*, **2015**, 42, 1733-9	5.6	18
73	Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy. *Abdominal Imaging*, **2015**, 40, 2557-65		31
72	Clinical implications of a multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance. *Journal of Urology*, **2015**, 193, 1943-1949	2.5	55
71	Cancer drug delivery: considerations in the rational design of nanosized bioconjugates. *Bioconjugate Chemistry*, **2014**, 25, 2093-100	6.3	60
70	Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. *Molecular Oncology*, **2014**, 8, 620-32	7.9	77
69	Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers. *BJU International*, **2014**, 114, E43-E49	5.6	95
68	Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. *Radiology*, **2014**, 270, 849-56	20.5	122
67	Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. *Journal of Nuclear Medicine*, **2014**, 55, 1986-92	8.9	112
66	Nanoparticles: take only pictures, leave only footprints. *Science Translational Medicine*, **2014**, 6, 260fs44	17.5	5
65	Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome. *Journal of the American College of Surgeons*, **2014**, 218, 163-9	4.4	26
64	Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. *Urology Practice*, **2014**, 1, 13-21	0.8	5
63	Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. *ACS Nano*, **2013**, 7, 717-24	16.7	187

62	Performance characteristics of a positron projection imager for mouse whole-body imaging. *Nuclear Medicine and Biology*, **2013**, 40, 321-30	2.1	2
61	Meeting the challenges of PET-based molecular imaging in cancer. *Expert Review of Molecular Diagnostics*, **2013**, 13, 671-80	3.8	1
60	Fully automated prostate segmentation on MRI: comparison with manual segmentation methods and specimen volumes. *American Journal of Roentgenology*, **2013**, 201, W720-9	5.4	42
59	Science to Practice: imaging cancer-associated fibroblasts--no innocent bystanders. *Radiology*, **2013**, 268, 617-8	20.5	1
58	Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. *Bioconjugate Chemistry*, **2012**, 23, 604-9	6.3	115
57	Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. *BJU International*, **2012**, 110, E694-700	5.6	48
56	Correlation of magnetic resonance imaging tumor volume with histopathology. *Journal of Urology*, **2012**, 188, 1157-1163	2.5	152
55	ESUR prostate MR guidelines 2012. *European Radiology*, **2012**, 22, 746-57	8	1779
54	Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. *Nature Medicine*, **2011**, 17, 1685-91	50.5	665
53	An MRI-compatible robotic system with hybrid tracking for MRI-guided prostate intervention. *IEEE Transactions on Biomedical Engineering*, **2011**, 58, 3049-60	5	73
52	Biologically optimized nanosized molecules and particles: more than just size. *Bioconjugate Chemistry*, **2011**, 22, 993-1000	6.3	136
51	Science to practice: angiogenic marker expression during tumor growth--can targeted US microbubbles help monitor molecular changes in the microvasculature?. *Radiology*, **2011**, 258, 655-6	20.5	2
50	Pilot study of FPPRGD2 for imaging (v)(3) integrin--how integral are integrins?. *Radiology*, **2011**, 260, 1-2	20.5	12
49	Toxicity of Organic Fluorophores Used in Molecular Imaging: Literature Review. *Molecular Imaging*, **2009**, 8, 7290.2009.00031	3.7	278
48	Can imaging gene expression in human mesenchymal stem cells be successful in large animals?. *Radiology*, **2009**, 252, 1-3	20.5	2
47	Commentary on "Computed tomography in the diagnosis of adrenal disease" and "Nonfunctioning adrenal masses: incidental discovery on computed tomography". *American Journal of Roentgenology*, **2009**, 192, 568-70	5.4	2
46	Nanoparticles in sentinel lymph node mapping. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2009**, 1, 610-23	9.2	42
45	Radiologic evaluation of hematuria: guidelines from the American College of Radiology appropriateness criteria. *American Family Physician*, **2008**, 78, 347-52	1.3	21

44	MRI of tumor angiogenesis. *Journal of Magnetic Resonance Imaging*, **2007**, 26, 235-49	5.6	232
43	Is it possible to quantify fluorescence during optical endoscopy?. *Radiology*, **2007**, 245, 307-8	20.5	1
42	The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis. *Expert Opinion on Drug Delivery*, **2007**, 4, 389-402	8	16
41	ACR Appropriateness Criteria on incidentally discovered adrenal mass. *Journal of the American College of Radiology*, **2006**, 3, 498-504	3.5	47
40	Contrast agents for imaging tumor angiogenesis: is bigger better?. *Radiology*, **2005**, 235, 1-2	20.5	25
39	System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner. *Magnetic Resonance in Medicine*, **2004**, 52, 683-7	4.4	114
38	Hereditary renal cancers. *Radiology*, **2003**, 226, 33-46	20.5	164
37	Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. *Journal of Magnetic Resonance Imaging*, **2003**, 17, 509-20	5.6	349
36	Imaging of hereditary renal cancer. *Radiologic Clinics of North America*, **2003**, 41, 1037-51	2.3	27
35	Special techniques for imaging blood flow to tumors. *Cancer Journal (Sudbury, Mass)*, **2002**, 8, 109-18	2.2	15
34	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma **2002**, 94, 2333		1
33	A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. *Annals of Surgical Oncology*, **2001**, 8, 741-5	3.1	52
32	Preferential arterial imaging using gated thick-slice gadolinium-enhanced phase-contrast acquisition in peripheral MRA. *Journal of Magnetic Resonance Imaging*, **2001**, 13, 714-21	5.6	3
31	A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). *Cancer*, **2001**, 92, 1577-90	6.4	68
30	Merging of intersecting triangulations for finite element modeling. *Journal of Biomechanics*, **2001**, 34, 815-9	2.9	52
29	Prostate cancer: what is the future role for imaging?. *American Journal of Roentgenology*, **2001**, 176, 17-22	3.4	30
28	PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. *Journal of Urology*, **2001**, 165, 1623-1624	2.5	7
27	PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. *Journal of Urology*, **2001**, 165, 777-781	2.5	159

26	A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar) **2001**, 92, 1577		1
25	Imaging of urea using chemical exchange-dependent saturation transfer at 1.5T. *Journal of Magnetic Resonance Imaging*, **2000**, 12, 745-8	5.6	51
24	Bolus-chase peripheral 3D MRA using a dual-rate contrast media injection. *Journal of Magnetic Resonance Imaging*, **2000**, 12, 769-75	5.6	16
23	Ferumoxide-enhanced MRI in patients with colorectal cancer and rising CEA: surgical correlation in early recurrence. *Magnetic Resonance Imaging*, **2000**, 18, 305-9	3.3	16
22	Case 18: adrenocorticotropic hormone-dependent Cushing syndrome. *Radiology*, **2000**, 214, 195-8	20.5	6
21	A PHASE 2 STUDY OF RADIO FREQUENCY INTERSTITIAL TISSUE ABLATION OF LOCALIZED RENAL TUMORS. *Journal of Urology*, **2000**, 163, 1424-1427	2.5	77
20	Automated bolus chase peripheral MR angiography: initial practical experiences and future directions of this work-in-progress. *Journal of Magnetic Resonance Imaging*, **1999**, 10, 376-88	5.6	97
19	Screening for Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy. *Medical and Pediatric Oncology*, **1999**, 32, 196-200		125
18	Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. *Journal of Urology*, **1999**, 161, 1475-9	2.5	189
17	MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. *Journal of Urology*, **1999**, 161, 395-398	2.5	79
16	Automated bolus chase peripheral MR angiography: Initial practical experiences and future directions of this work-in-progress **1999**, 10, 376		2
15	Clinical differentiation between Proteus syndrome and hemihyperplasia: description of a distinct form of hemihyperplasia. *American Journal of Medical Genetics Part A*, **1998**, 79, 311-8		83
14	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Human Mutation*, **1998**, 12, 417-23	4.7	406
13	From needles to numbers: can noninvasive imaging distinguish benign and malignant adrenal lesions?. *World Journal of Urology*, **1998**, 16, 29-34	4	13
12	PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. *Journal of Urology*, **1998**, 159, 1148-1151	2.5	9
11	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene **1998**, 12, 417		12
10	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nature Genetics*, **1997**, 16, 68-73	36.3	1289
9	Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. *Journal of Urology*, **1995**, 153, 913-916	2.5	80

8	Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. *Journal of Urology*, **1995**, 153, 907-912	2.5	154
7	Hereditary papillary renal cell carcinoma. *Journal of Urology*, **1994**, 151, 561-6	2.5	235
6	Evaluation of color Doppler intraoperative ultrasound in parenchymal sparing renal surgery. *Journal of Urology*, **1994**, 152, 1984-7	2.5	35
5	Dynamic enhanced magnetic resonance imaging of testicular perfusion in the rat. *Journal of Urology*, **1993**, 149, 1195-7	2.5	19
4	Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. *Journal of Urology*, **1993**, 150, 463-6	2.5	104
3	Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. *Cancer*, **1993**, 71, 1797-800	6.4	65
2	Intratesticular masses associated with abnormally functioning adrenal glands. *Journal of Clinical Ultrasound*, **1992**, 20, 51-8	1	17
1	A report of familial carotid body tumors and multiple extra-adrenal pheochromocytomas. *Journal of Urology*, **1991**, 145, 1040-2	2.5	28